ALIBABA-CLOUD
19.3.2020 05:26:06 CET | Business Wire | Press release
Alibaba Cloud, the data intelligence backbone of Alibaba Group, said today it has offered medical personnel around the world advanced cloud-based technology applications in the fight against the COVID-19 pandemic.
The artificial intelligence-enhanced innovations are based on learnings and insights garnered during the initial outbreak of the virus.
The series of cloud-native anti-coronavirus solutions stem from joint efforts of Alibaba Cloud’s solution experts, scientists and researchers from Alibaba DAMO Academy and the technical team at DingTalk, one of the platforms UNESCO has tabbed as facilitating distance learning during the coronavirus outbreak.
While DingTalk might be better-known for supporting more than 120 million students across China with their live-streamed online classes, the team has taken it up a notch to launch DingTalk’s International Medical Expert Communication Platform , hosted on Alibaba Cloud. It provides a means of free communication for medical workers all over the world to directly contact doctors from medical institutions such as the First Affiliated Hospital of Zhejiang University and others in China, who have been on the frontline of the COVID-19 battle.
Through video conferencing and real-time AI translation into 11 languages (Arabic, Bahasa, Chinese, English, French, Japanese, Russian, Spanish, Thai, Turkish, and Vietnamese), Alibaba Cloud aims to build a virtual community, inviting Chinese doctors to share their experiences and answer questions from global peers.
From Alibaba DAMO Academy, a global research initiative by Alibaba, three proven solutions are being made available via free trial for medical professionals and research institutes worldwide. Alibaba Cloud will work with local partners to deploy relevant services and solutions in accordance with local laws and regulations.
Epidemic Prediction Solution models epidemic characteristics of COVID-19 in a particular region, providing estimates of size, peak time and duration of the epidemic, as well as the spreading trends under three conditions - optimistic, neutral, and pessimistic. Based on machine learning, the algorithm was already tested on 31 provincial data in China and averaged 98% accuracy. It can serve as a reference to policymakers and medical researchers on prevention and control measures, medical resource allocation and travel advisories.
CT Image Analytics Solution is a CT image analytics technology service that can significantly improve testing accuracy and detection efficiency for diagnosing COVID-19. With deep-learning algorithms trained by data in China, the trained model can predict the probability of different pneumonia types, including the variety associated with COVID-19. It also performs computations of the proportion of lesions and the affected volume ratio to the entire lungs, by using the lung segmentation method. The whole test takes about 3 to 4 seconds to run and 15 to 16 seconds of transmission time, making it nearly 60 times faster than human detection. More than 160 hospitals in China are currently using the solution.
Genome Sequencing for Coronavirus Diagnostic Solution , an AI algorithm from Alibaba DAMO Academy and running on Alibaba Cloud, is a virus genome sequencing solution for coronavirus analytics, including viral genetic data screening, evolutionary analysis, protein structure analysis, and diagnostic reporting. It can complete the diagnosis of new coronavirus within 14 hours, which is five times faster than other available sequencing solutions in China. It can screen more than 20 people simultaneously, making the averaged time for each sample just around half an hour, much shorter than the normal two hours with the PCR method. The solution helps disease control centers, hospitals and clinics, and laboratories to address challenges such as insufficient nucleic acid detection capacity, high false-negative rates of the PCR method, and possible virus mutations.
Supporting advanced innovations during emergencies like COVID-19 requires extremely scalable supercomputing power. For this, Alibaba Cloud offers Elastic High-Performance Computing (E-HPC) Solution for Life Sciences , a cloud-native high-performance computing cluster solution designed for researchers working on life sciences applications, especially for Computational-Driven-Drug-Design (CDDD) and AI-Driven-Drug-Design (AIDDD). The solution already supports 20 research groups in China. For example, the intelligent CT diagnostic system on COVID-19 pneumonia developed by Tsinghua University can complete diagnosing in 10 seconds, and the performance of gene assembly by Sun Yat-sen University is accelerated by 25% utilizing the solution. Alibaba Cloud has also partnered with Global Health Drug Discovery Institute (GHDDI) in Beijing to launch an AI-driven-drug-discovery platform based on E-HPC.
For those looking to learn more about key lessons and experience from doctors and other medical personnel at the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), the Jack Ma Foundation and Alibaba Foundation have also shared a handbook from the medical personnel covering what they’ve learned every step of the way, from screening to diagnosis and treatment of patients who contracted COVID-19. Medical personnel can download the handbook at https://covid-19.alibabacloud.com/ .
For more information about the above solutions available for global medical communities and businesses, please visit: https://www.alibabacloud.com/campaign/supports-your-business-anytime
Notes to the editors
The information in this press release should not be interpreted as offering medical advice or diagnostics, which should be given exclusively by authorized medical professionals in relevant jurisdiction. All data referred to are those as of writing of this summary, and Alibaba Cloud explicitly disclaim any warranty for accuracy or performance.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (www.alibabacloud.com ), the data intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005821/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
